PMID- 37639902
OWN - NLM
STAT- Publisher
LR  - 20231012
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 177
DP  - 2023 Oct
TI  - Prevalence of type 2 diabetes diagnoses in the perioperative and survivorship 
      periods following surgical management of endometrial cancer: An opportunity for 
      screening and intervention?
PG  - 46-52
LID - S0090-8258(23)01438-5 [pii]
LID - 10.1016/j.ygyno.2023.08.009 [doi]
AB  - OBJECTIVE: To determine the prevalence of Type 2 diabetes mellitus (T2DM) 
      diagnoses during the peri-operative and survivorship periods in patients 
      following surgical management of endometrial cancer (EC). METHODS: An 
      IRB-approved, retrospective single-institution cohort study was performed in 
      patients who underwent surgical management of EC from 2014 to 2020. The 
      perioperative period was defined as the 30 days before and after surgery. T2DM 
      diagnoses occurring during survivorship were recorded. T2DM diagnoses were 
      defined by a HgbA1c >/=6.5% or a random blood glucose >/=200 mg/dL. Sequelae of 
      peri-operative T2DM and predictors of future T2DM were examined utilizing 
      univariate analysis. RESULTS: Of 519 patients meeting inclusion criteria, 37 
      (7.1%) were diagnosed with T2DM in the perioperative period. Patients diagnosed 
      with T2DM in the perioperative period had significantly higher BMI (p = 0.006) 
      compared to no T2DM, but there were no significant differences in age (p = 0.20), 
      ethnicity/race (p > 0.05) or ECOG score (p = 0.19). The rates of intraoperative 
      complications between groups did not significantly differ, except for vascular 
      complications (p = 0.005), and the incidence of any postoperative complication 
      was higher in the perioperative T2DM group (p = 0.01). With a median follow-up of 
      29 months [range 11.6-49.0 months], an additional 18.3% (n = 88) of the cohort 
      met diagnostic criteria for T2DM. BMI (p < 0.001), perioperative glucose 
      (p < 0.001), and HgbA1c (p = 0.002) demonstrate risk for a T2DM diagnosis during 
      survivorship. CONCLUSION(S): In this retrospective cohort of EC patients, 25.4% 
      were diagnosed with T2DM, with the majority diagnosed in the survivorship period. 
      Surgical management and subsequent surveillance of EC presents an opportunity to 
      diagnose at-risk patients with T2DM.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Morton, Molly
AU  - Morton M
AD  - Division of Gynecologic Oncology, The Ohio State University Wexner Medical 
      Center, The James Cancer Hospital and Solove Research Institute, Starling Loving 
      Hall, M210, 320 W. 10(th) Avenue, Columbus, OH 43210, USA. Electronic address: 
      molly.morton@osumc.edu.
FAU - McLaughlin, Eric M
AU  - McLaughlin EM
AD  - Center for Biostatistics, The Ohio State University, Columbus, OH 43210, USA.
FAU - Calo, Corinne A
AU  - Calo CA
AD  - Division of Gynecologic Oncology, OhioHealth, Columbus, OH, USA.
FAU - Lightfoot, Michelle
AU  - Lightfoot M
AD  - Division of Gynecologic Oncology, New York University, New York, NY, USA.
FAU - Bixel, Kristin L
AU  - Bixel KL
AD  - Division of Gynecologic Oncology, The Ohio State University Wexner Medical 
      Center, The James Cancer Hospital and Solove Research Institute, Starling Loving 
      Hall, M210, 320 W. 10(th) Avenue, Columbus, OH 43210, USA.
FAU - Cohn, David E
AU  - Cohn DE
AD  - Division of Gynecologic Oncology, The Ohio State University Wexner Medical 
      Center, The James Cancer Hospital and Solove Research Institute, Starling Loving 
      Hall, M210, 320 W. 10(th) Avenue, Columbus, OH 43210, USA.
FAU - Cosgrove, Casey M
AU  - Cosgrove CM
AD  - Division of Gynecologic Oncology, The Ohio State University Wexner Medical 
      Center, The James Cancer Hospital and Solove Research Institute, Starling Loving 
      Hall, M210, 320 W. 10(th) Avenue, Columbus, OH 43210, USA.
FAU - Copeland, Larry J
AU  - Copeland LJ
AD  - Division of Gynecologic Oncology, The Ohio State University Wexner Medical 
      Center, The James Cancer Hospital and Solove Research Institute, Starling Loving 
      Hall, M210, 320 W. 10(th) Avenue, Columbus, OH 43210, USA.
FAU - O'Malley, David M
AU  - O'Malley DM
AD  - Division of Gynecologic Oncology, The Ohio State University Wexner Medical 
      Center, The James Cancer Hospital and Solove Research Institute, Starling Loving 
      Hall, M210, 320 W. 10(th) Avenue, Columbus, OH 43210, USA.
FAU - Nagel, Christa I
AU  - Nagel CI
AD  - Division of Gynecologic Oncology, The Ohio State University Wexner Medical 
      Center, The James Cancer Hospital and Solove Research Institute, Starling Loving 
      Hall, M210, 320 W. 10(th) Avenue, Columbus, OH 43210, USA.
FAU - Chambers, Laura M
AU  - Chambers LM
AD  - Division of Gynecologic Oncology, The Ohio State University Wexner Medical 
      Center, The James Cancer Hospital and Solove Research Institute, Starling Loving 
      Hall, M210, 320 W. 10(th) Avenue, Columbus, OH 43210, USA.
LA  - eng
PT  - Journal Article
DEP - 20230826
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
SB  - IM
OTO - NOTNLM
OT  - Endometrial cancer
OT  - Survivorship
OT  - Type 2 diabetes mellitus
COIS- Conflict of interest statement C.M.C. has received funds from AstraZeneca and 
      GlaxoSmithKline. D.O.M. receives institutional research funding from AbbVie, 
      Agenus, Aravive, AstraZeneca, Boston Biomedical, Clovis Oncology, Eisai, 
      Exelixis, Genmab, GOG Foundation, ImmunoGen, IOVANCE Biotherapeutics, Leap 
      Therapeutics, Merck, Mersana Therapeutics, NRG Oncology, OncoQuest, Precision 
      Therapeutics, Regeneron Pharmaceuticals, Rubuis Therapeutics, Sutro Biopharma, 
      TESARO, Advaxis, Alkermes, Arcus Biosciences, BeiGene, Bristol Myers Squibb, 
      Deciphera Pharma, EMB Serono, Genentech, GlaxoSmithKline, Hoffman-La Roche, 
      Incyte Corporation, Karyopharm, Ludwig Institute, Merck Sharp & Dohme Corp, NCI, 
      NovoCure, OncoC4 Inc., Pfizer Inc., Prelude Therapeutics, RTOG, Seattle Genetics 
      (SeaGen), SWOG, and Verastem Inc. L.Copeland reports personal fees from Celsion 
      Corporation, personal fees and other from Corcept Therapeutics, Inc., personal 
      fees from Elevar Therapeutics, grants and personal fees from GSK, Inc., personal 
      fees from Myriad Genetics, Inc., personal fees from Rubius Therapeutics, personal 
      fees from Sorrento Therapeutics, personal fees from Tarveda Therapeutics, 
      personal fees from Toray Industries, Inc., grants from Abbvie, grants from 
      Advaxis, grants from Agenus, grants from Ajinomoto, grants from Array BioPharm, 
      grants from AstraZeneca, grants from Bristol Myers Squbb, grants from Clovis 
      Oncology, grants from Deciphera Parma, grants from Eisai, grants from EMD Serono 
      Inc., grants from ERGOMED Clinical Research, grants from Exelixis, grants from 
      Genentech/Roche, grants from Genmab, grants from Hoffman-LaRoche, grants and 
      personal fees from Immunogen, grants from Incyte Corporation, grants from Iovance 
      Biotherapeutics, grants from InVentive Health Clinical, grants from Jansen R&D, 
      grants from Leap Therapeutics, grants from Ludwig Institute for Pharmaceuticals, 
      grants from Merck, grants from Mersana Therapeutics, Inc., grants from Novocure, 
      grants from Novartis Pharmaceuticals, grants from OncoQuest, grants from PRA 
      International, grants from Regeneron Pharnaceuticals, grants from Seattle 
      Genetics, grants from Serono, grants from Sutro Biopharm, grants from Tesaro 
      (GSK), grants from Arcus Biosciences, Inc., grants from Sumitomo Dainippon Pharma 
      Oncolgy, grants from Cerulean Pharma, grants from Karyopharm, grants from BeiGene 
      USA, Inc., grants from Ovagene, grants from Pfizer Inc., grants from Pharma Mar 
      USA, Inc., grants from Precision Therapeutics, Inc., grants from Sanofi, grants 
      from Stemcentrx, Inc., grants from TRACON Pharm, grants from Verastem, Inc., 
      personal fees from VBL Therapeutics, Inc., personal fees from OncoNova, Inc., 
      personal fees from Inx Med, personal fees from Luzsana Biotechnology, outside the 
      submitted work; .D.O.M. receives consulting fees from AbbVie, Adaptimmune, Agenus 
      Inc., Arquer Diagnostics, Arcus Biosciences Inc., AstraZeneca, Atossa 
      Therapeutics, Boston Biomedical, Cardiff Oncology, Celcuity, Clovis Oncology, 
      Corcept Therapeutics, Duality Bio, Eisai, Elevar, Exelixis, Genentech Inc., 
      Genelux, GlaxoSmithKline, GOG Foundation, Hoffman-La Roche Inc., ImmunoGen Inc., 
      Imvax, InterVenn, INXMED, IOVANCE Biotherapeutics, Janssen, Jazz Pharmaceuticals, 
      Laekna, Leap Therapeutics Inc., Luzsana Biotechnology, Merck & Co, Merck Sharp & 
      Dohme Corp, Mersana Therapeutics Inc., Myriad, Novartis, NovoCure, OncoC4 Inc., 
      Onconova, Regeneron Pharmaceuticals Inc., Repimmune, R Pharm, Roche Diagnostics, 
      Seattle Genetics (SeaGen), Sorrento, Sutro Biopharma, Tarveda Therapeutics, 
      Toray, Trillium, Umoja, Verastem Inc., VBL Therapeutics, Vincerx Pharma, Xencor, 
      and Zentalis. No research or consulting funding was utilized in the execution or 
      formulation of this study.
EDAT- 2023/08/29 00:41
MHDA- 2023/08/29 00:41
CRDT- 2023/08/28 18:06
PHST- 2023/06/14 00:00 [received]
PHST- 2023/08/11 00:00 [revised]
PHST- 2023/08/18 00:00 [accepted]
PHST- 2023/08/29 00:41 [pubmed]
PHST- 2023/08/29 00:41 [medline]
PHST- 2023/08/28 18:06 [entrez]
AID - S0090-8258(23)01438-5 [pii]
AID - 10.1016/j.ygyno.2023.08.009 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2023 Oct;177:46-52. doi: 10.1016/j.ygyno.2023.08.009. Epub 2023 
      Aug 26.